WLF Ruling Offers No Viable Alternatives For Encouraging sNDAs - FDA Appeal

The ruling overturning FDA's regulation of off-label reprint dissemination offers no viable alternatives for encouraging companies to file supplemental new drug applications, FDA's appeal of Washington Legal Foundation v. Henney argues.